DiaSorin FY 2025 slides: stable growth amid headwinds, eyes acceleration By Investing.com

Revenue of €1,195m in FY2025 (+1% YoY) with adjusted EBITDA €394m (flat YoY) and full-year adjusted EBITDA margin maintained at 33% (Q4 margin 31%). Net income fell 20% to €150m and adjusted net €223m (-6%); the stock closed €64.02 (+0.61% on the day, -32% YTD). Management guides FY2026 revenue +5–6% at constant FX and adj. EBITDA margin ~32–33%, assuming EUR/USD 1.18 (vs 1.13 in 2025), noting each €0.01 FX move impacts revenue by ~€6–7m and EBITDA by ~€2–3m. Product catalysts (LIAISON PLEX ramp, ~150 installs, Quest contract, LIAISON NES commercial launch in Q3 2026) offset China VBP headwinds and tariff/mix pressure, making execution in China and respiratory seasonality key risks to monitor.

Analysis

The headline takeaway is a structural re‑rate candidate: a diagnostics OEM that successfully shifts revenue toward hospital specialty menus and locks in commercial lab contracts creates durable high‑margin recurring consumable streams. That dynamic benefits counterparties who own the channel (commercial labs and distributors) because they capture more of the downstream margin and volume optionality as new panels scale, while peers with heavier exposure to commoditized, volume‑sensitive segments will see greater margin pressure. Currency sensitivity and China reimbursement risk are real convexities — a few cents move in EUR/USD or another VBP tranche in China materially alters annual EBITDA, so timing of FX moves and policy events should be treated as catalysts rather than background noise. Finally, near‑term seasonality in respiratory testing creates a predictable volatility window: weak early‑year respiratory volumes compress molecular revenue now but set up asymmetric upside if new panels and platform installs execute in H2, concentrating stock performance around product approvals and large commercial rollouts.

Key Decisions for Investors

• Long DGX (Quest Diagnostics) — 6–12 month horizon. Rationale: counterparty to platform adoption; revenue share upside from exclusive respiratory panel supply; trade as a directional long with a 15–25% target if panel rollouts accelerate. Risk: execution shortfall from lab adoption or pricing disputes; stop at 8% trailing loss.
• Long MCK (McKesson) — 3–9 month horizon via outright equity or buy‑dated calls. Rationale: distributor exposure to platform consumables and widened hospital purchasing; asymmetric upside if distribution volumes re‑accelerate in H2. Risk/reward: pay ~1–2% notional in calls for 2–4x upside on adoption news; hedge with small put position to limit downside to ~6–8%.
• Pair trade: long DGX / short broad diagnostics OEM exposure (synthetic via sector ETF or specific European OEM) — 6–12 months. Rationale: capture channel consolidation benefits vs platform‑owner margin compression from China/VBP; target spread compression of 10–15%. Risk: sectorwide rallies erase spread — cap losses by sizing short to 50–60% of long notional.
• Macro hedge: buy modest protection in index puts (e.g., SPX 2–3 month) sized to 1–2% portfolio risk. Rationale: UBS macro optimism raises beta but also raises drawdown risk if macro surprise (FX, China policy) reverses; protection pays off in a rapid risk‑off that correlates with biotech/healthcare selloffs.